This includes the expression of CD80/CD86 and PD-L1 ligands by the tumor [or the tumor-associated antigen-presenting cells (APCs)] that interact with the negative regulators of T cell activation, the CTLA-4 and PD-1 receptors, respectively, expressed at the membrane of the activated immune cells [reviewed in [212, 213]]. This evidence concerns the gene CD80 and neoplasm.